About

​PulManage, Inc is a software company specializing in remote monitoring of chronic lung disease such as COPD. The proprietary platform utilizes a mobile application to collect spirometry data from a handheld medical device and push that information directly into a secure, web-based application for patients to document symptoms and respiratory function. Simultaneously, providers can survey and trend the patient's condition remotely. The platform can be utilized to create value and document physiologic and therapeutic response longitudinally. About PulManage, Inc. PulManage, Inc., a digital health company, has developed a platform for chronic lung disease that pairs with FDA-approved lung-function devices. The platform provides critical lung-function data coupled with symptom management and respiratory biomarkers for patients and medical teams in a secure portal. The system allows medical providers and clinical researchers to survey respiratory status remotely. The company is developing predictive algorithms using AI to better understand disease patterns and mitigate risk. More than 24 million people in the United States live with chronic lung diseases such as COPD or asthma. When combined with lung cancer and respiratory diseases like COVID-19 or influenza, lung disease is the number one cause of death by disease in America. About Pulmanage, Inc. PulManage, Inc., a digital health company, has developed a platform for chronic lung disease that pairs with FDA-approved lung-function devices. The platform provides critical lung-function data coupled with symptom management and respiratory biomarkers for patients and medical teams in a secure portal. The system allows medical providers and clinical researchers to survey respiratory status remotely. The company is developing predictive algorithms using AI to better understand disease patterns and mitigate risk. More than 24 million people in the United States live with chronic lung diseases such as COPD or asthma. When combined with lung cancer and respiratory diseases like COVID-19 or influenza, lung disease is the number one cause of death by disease in America. PulManage, Inc. is transforming respiratory clinical trials in rare diseases by solving persistent challenges like data variability, patient recruitment, and operational inefficiencies. Traditional in-person spirometry is burdensome and technician-dependent, leading to low data fidelity. PulManage’s compliant, scalable platform provides real-time, high-quality remote spirometry guided by credentialed respiratory therapists, reducing variability by up to 40% and ensuring global ATS/ERS compliance. Frequent, standardized assessments and real-time analytics enhance data fidelity and disease characterization. Shared dashboards improve sponsor oversight. Proven in rural COPD studies, the platform boosts enrollment, communication, and data quality. It’s used by academic centers and a rare disease community for trials and real-world evidence, with future support for multilingual trials, wearables, and forecasting analytics.